Buy Ventoxen 100 MG (Venetoclax) - Mediaid pharmacy

Ventoxen 100 MG (Venetoclax)

Product Name : Ventoxen (Venetoclax)
Generic Name : Venetoclax
Formulation :
Available Pack Size :
Available Strengths : 100mg
Registrations : Bangladesh

Message Us on WhatsApp

Product Information

Ventoxen (Venetoclax) 100mg is a selective, oral BCL-2 inhibitor used to treat Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma (CLL/SLL) and, in combination with certain other agents, newly diagnosed Acute Myeloid Leukaemia (AML) in adults unsuitable for intensive chemotherapy. It works by inhibiting the anti-apoptotic protein BCL-2, which many leukaemic cells overexpress to evade programmed cell death; blocking BCL-2 restores the cell’s ability to undergo apoptosis, triggering rapid death of leukaemic cells. Manufactured by Everest Pharmaceuticals Ltd., Bangladesh and globally supplied by Mediaid Pharmacy with worldwide shipping.

Basic Product Information of Ventoxen (Venetoclax) 100mg

Brand Name	Ventoxen (Venetoclax)
Generic Name	Venetoclax INN
Drug Class	Selective BCL-2 Inhibitor
Available Strength	100mg
Formulation	Film-Coated Tablet
Pack Size	60 Tablets per Pack
Primary Indication	Chronic Lymphocytic Leukaemia/SLL and Newly Diagnosed Acute Myeloid Leukaemia
Regulatory Approvals	USFDA Approved (CLL/SLL and AML). EMA Approved. Carries an FDA Boxed Warning for tumour lysis syndrome.
Originator Brand	Venclexta / Venclyxto by AbbVie and Genentech (Roche)
Manufacturer	Everest Pharmaceuticals Ltd., Dhaka, Bangladesh
Global Supplier	Mediaid Pharmacy, Worldwide Shipping Available
Registration	Registered in Bangladesh
Storage Conditions	Store between 20 and 25 degrees Celsius. Do not freeze. Dispense and keep in the original container to protect from moisture.

Important note on strengths: Venetoclax requires a mandatory, gradual 5-week dose ramp-up when a patient first starts treatment (typically 20mg, then 50mg, then 100mg, then 200mg, then 400mg once daily), specifically to reduce the risk of tumour lysis syndrome from very rapid leukaemic cell death. This 100mg product alone cannot safely deliver the lower starting doses (20mg and 50mg) required at the beginning of that schedule. Patients beginning Ventoxen for the first time will need access to the full range of starting-dose strengths from their treating oncology team or pharmacy; this 100mg tablet is generally used during the later stages of ramp-up or for ongoing maintenance dosing once titration is complete. Please confirm strength availability with your supplier before dispensing to a treatment-naive patient.

How Ventoxen (Venetoclax) Works

Ventoxen contains Venetoclax, a selective, orally bioavailable small-molecule inhibitor of BCL-2 (B-cell lymphoma 2), an anti-apoptotic protein. Many leukaemic cells, particularly in CLL and AML, overexpress BCL-2 as a survival mechanism, using it to resist the normal cellular process of programmed cell death (apoptosis) and evade destruction by chemotherapy.

By binding directly to BCL-2 and displacing pro-apoptotic proteins that BCL-2 would otherwise sequester and neutralise, Ventoxen restores the cell’s normal apoptotic signalling, triggering rapid, targeted death of leukaemic cells. Because this mechanism can cause very rapid and extensive tumour cell death, particularly early in treatment or in patients with a high tumour burden, Ventoxen requires a carefully staged dose ramp-up and close monitoring to manage the risk of tumour lysis syndrome (TLS).

Ventoxen is taken as a once-daily oral tablet with food and water, used either as monotherapy, in combination with an anti-CD20 antibody (rituximab or obinutuzumab) for CLL/SLL, or in combination with a hypomethylating agent or low-dose cytarabine for AML.

Indications for Ventoxen (Venetoclax)

Ventoxen (Venetoclax) is indicated for the following conditions:

CLL/SLL, in Combination with Rituximab

For adult patients with CLL/SLL who have received at least one prior therapy, given in combination with rituximab for a total treatment duration of 24 months from Cycle 1 Day 1 of rituximab.

CLL/SLL Monotherapy

For adult patients with 17p deletion or TP53 mutation who have failed or are unsuitable for a B-cell receptor pathway inhibitor, or without these mutations who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.

Newly Diagnosed Acute Myeloid Leukaemia (AML)

In combination with azacitidine, decitabine, or low-dose cytarabine, for adult patients newly diagnosed with AML who are 75 years of age or older, or who have comorbidities that preclude intensive induction chemotherapy.

Benefits of Ventoxen (Venetoclax) 100mg

Fixed-Duration Treatment Option

Unlike some continuous CLL therapies, Ventoxen in combination with rituximab or obinutuzumab offers a defined treatment duration (12 or 24 months), rather than indefinite daily therapy.

Effective in High-Risk Genetics

Ventoxen monotherapy is specifically approved for CLL patients with 17p deletion or TP53 mutation, high-risk genetic features associated with poorer response to many other therapies.

Option for Older or Frailer AML Patients

Combined with a hypomethylating agent or low-dose cytarabine, Ventoxen offers an effective option for newly diagnosed AML patients unable to tolerate intensive induction chemotherapy.

Affordable Alternative to Venclexta

Ventoxen contains the same active ingredient as Venclexta by AbbVie and Genentech, at a significantly lower cost, making advanced leukaemia therapy more financially accessible.

Convenient Oral Dosing

Once the ramp-up phase is complete, Ventoxen is taken as a single oral tablet once daily, supporting long-term outpatient management.

WHO-GMP Certified Manufacturing

Produced by Everest Pharmaceuticals Ltd. under WHO-GMP-compliant manufacturing standards, with stability testing and HPLC analysis supporting consistent quality in every batch.

How to Take Ventoxen (Venetoclax)

Route: Oral, taken with a meal and water, at approximately the same time each day. Tablets should be swallowed whole and not chewed, crushed, or broken.

CLL/SLL ramp-up schedule: Treatment begins with a mandatory 5-week dose ramp-up: 20mg once daily (week 1), 50mg once daily (week 2), 100mg once daily (week 3), 200mg once daily (week 4), and 400mg once daily from week 5 onward, with TLS prophylaxis (hydration and, where indicated, antihyperuricaemic therapy) and laboratory monitoring at each dose increase.

Post-ramp-up dose for CLL/SLL monotherapy: 400mg once daily, continued until disease progression or unacceptable toxicity.

AML dosing: A shorter ramp-up schedule is used (typically over 3 to 4 days) before reaching the target dose, which is 400mg once daily in combination with a hypomethylating agent, or 600mg once daily in combination with low-dose cytarabine, exactly as directed by the treating haemato-oncologist.

Missed dose: If a dose is missed by less than 8 hours, take it as soon as possible on the same day; if more than 8 hours have passed, skip the missed dose and resume the normal schedule the next day.

Hepatic impairment: Reduce the dose by 50% in patients with severe hepatic impairment (Child-Pugh Class C); close monitoring for adverse reactions is advised.

Renal impairment: Patients with reduced renal function, particularly those with a high tumour burden, are at increased risk of tumour lysis syndrome and require closer monitoring and more intensive prophylaxis during dose initiation.

Paediatric use: The safety and efficacy of Ventoxen in paediatric patients have not been established. No data are currently available.

Boxed Warning – Prescription Medication. Ventoxen carries a boxed warning for Tumour Lysis Syndrome (TLS), a potentially life-threatening complication caused by rapid breakdown of leukaemic cells, which can lead to acute kidney failure, dangerous heart rhythm disturbances, and sudden death. TLS risk is highest during the initial ramp-up phase and in patients with a high tumour burden. Appropriate hydration, laboratory monitoring, and, where indicated, antihyperuricaemic prophylaxis are required at treatment initiation and with each dose increase. Ventoxen must only be prescribed and closely monitored by a haemato-oncologist experienced in managing TLS risk.

Monitoring and Dosage Adjustments

Regular monitoring is essential throughout Ventoxen treatment, and especially intensive during dose initiation. Your haemato-oncology team will assess tumour burden before starting treatment to determine your individual TLS risk category, and will monitor blood chemistry (potassium, phosphate, calcium, uric acid, and creatinine) before each dose increase and periodically thereafter. Monitoring also includes complete blood counts for neutropenia and other cytopenias, and vigilance for signs of infection. Report any muscle cramps, weakness, confusion, decreased urination, irregular heartbeat, nausea, vomiting, or fever to your doctor immediately, especially during the first weeks of treatment or after any dose increase.

Drug Interactions and Important Information

Venetoclax is a major substrate of CYP3A4 and P-glycoprotein (P-gp), and its exposure can be dramatically increased by strong CYP3A inhibitors; in studies, strong CYP3A/P-gp/BCRP inhibitors increased Venetoclax exposure by several-fold. Strong CYP3A inhibitors should be avoided during the ramp-up (dose initiation) phase, and if unavoidable at the steady maintenance dose, a substantial dose reduction is required, as directed by the prescribing physician. Avoid grapefruit, grapefruit juice, Seville oranges, and starfruit throughout treatment, as these also inhibit CYP3A.

Strong or moderate CYP3A inducers may reduce Ventoxen’s effectiveness and should generally be avoided. Women of childbearing potential must use highly effective contraception during treatment and for at least 30 days after the final dose. Breastfeeding is not recommended during treatment. Always inform your physician of all medications, supplements, and herbal products you are currently taking before starting Ventoxen.

Side Effects and Precautions

Common Side Effects

Diarrhoea

Nausea and vomiting

Fatigue

Decreased appetite

Upper respiratory tract infection

Low blood counts (neutropenia, anaemia, thrombocytopenia)

Serious Warnings and Precautions

Tumour lysis syndrome, potentially fatal, especially at treatment initiation. See boxed warning.

Severe neutropenia and risk of serious infection.

Immune-related complications when used with anti-CD20 antibodies (rituximab or obinutuzumab).

Hepatotoxicity, requiring periodic liver function monitoring.

Embryo-foetal toxicity. Not recommended during pregnancy or breastfeeding.

Who Should Use Ventoxen (Venetoclax)?

Ventoxen is suitable for adult patients with Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma, whether previously treated or presenting with high-risk 17p deletion/TP53 mutation, and for adult patients with newly diagnosed Acute Myeloid Leukaemia who are 75 years or older or otherwise unsuitable for intensive induction chemotherapy. It is prescribed by haemato-oncologists experienced in managing TLS risk and the specific combination regimens Ventoxen is used within. A thorough medical assessment including tumour burden evaluation, baseline blood chemistry, renal function, and blood counts is required before initiating treatment.

Manufacturer: Everest Pharmaceuticals Ltd.

Everest Pharmaceuticals Ltd. is a vertically integrated pharmaceutical company based in Dhaka, Bangladesh, focused on complex, technology-driven specialty medicines across oncology, nephrology, and virology. Operating under Bangladesh’s TRIPS/Doha Declaration exemption for least-developed countries, Everest manufactures advanced generics such as Ventoxen under WHO-GMP-compliant standards, with rigorous stability testing and HPLC analysis supporting each batch. Everest’s stated mission is to make high-cost, life-saving medicines accessible and affordable to patients around the world. Ventoxen is one of Everest’s specialty oncology products, offering a bioequivalent alternative to Venclexta by AbbVie and Genentech at a fraction of the cost.

Global Supplier: Mediaid Pharmacy with Worldwide Shipping

Mediaid Pharmacy is a trusted global supplier of specialty and oncology medications. We ensure Ventoxen (Venetoclax) is accessible to patients and healthcare providers worldwide through reliable worldwide shipping. Whether you are located in South Asia, the Middle East, Africa, Europe, or beyond, Mediaid Pharmacy provides fast and reliable delivery with full order support. Contact us directly via WhatsApp, phone, or WeChat for pricing, availability, and delivery enquiries.

Why Choose Ventoxen (Venetoclax) from Mediaid Pharmacy?

Ventoxen represents a genuine shift in leukaemia treatment, directly targeting the survival mechanism many leukaemic cells depend on. As the generic equivalent of Venclexta by AbbVie and Genentech, it delivers the same active ingredient, Venetoclax, with the same proven BCL-2 inhibition mechanism at a dramatically more affordable price. Manufactured by Everest Pharmaceuticals Ltd. under WHO-GMP-compliant standards and distributed globally by Mediaid Pharmacy, Ventoxen gives patients worldwide access to advanced leukaemia therapy without the financial burden of brand-name alternatives. For patients and physicians seeking a proven, affordable, and accessible Venetoclax option with worldwide delivery, Ventoxen from Mediaid Pharmacy is the trusted choice.

Frequently Asked Questions About Ventoxen (Venetoclax)

What is Ventoxen (Venetoclax) used for?

Ventoxen (Venetoclax) is used to treat adult patients with Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma, either as monotherapy or combined with rituximab or obinutuzumab, and adult patients with newly diagnosed Acute Myeloid Leukaemia who cannot tolerate intensive chemotherapy, combined with a hypomethylating agent or low-dose cytarabine. It works by blocking BCL-2, a protein leukaemic cells use to resist death.

How should I take Ventoxen (Venetoclax)?

Ventoxen is taken orally, once daily, with food and water. Treatment always begins with a gradual, mandatory dose ramp-up over several weeks to reduce the risk of tumour lysis syndrome, before reaching the target maintenance dose. This 100mg tablet is generally used during the later part of ramp-up or for maintenance dosing; the lower starting doses require separate, lower-strength tablets. Always follow your haemato-oncologist’s exact instructions.

What strength is Ventoxen available in?

This Ventoxen pack is supplied as a 100mg tablet, in a pack of 60 tablets. Because Venetoclax requires a staged dose ramp-up starting at much lower doses (20mg and 50mg), patients beginning treatment for the first time will also need access to those lower strengths; please confirm availability with your supplier.

Is Ventoxen the same as Venclexta (Venetoclax by AbbVie)?

Yes. Ventoxen is the generic equivalent of Venclexta (also marketed as Venclyxto in some regions). Both contain the same active ingredient, Venetoclax, and work through the same BCL-2 inhibition mechanism. Ventoxen is manufactured by Everest Pharmaceuticals Ltd. in Bangladesh and offers the same clinical mechanism as Venclexta at a significantly lower cost.

What are the side effects of Ventoxen (Venetoclax)?

Common side effects include diarrhoea, nausea, fatigue, decreased appetite, and low blood counts. Ventoxen carries a boxed warning for tumour lysis syndrome, a potentially fatal complication that requires careful monitoring, especially during the initial dose ramp-up. Always consult your haemato-oncology team for a complete assessment of your individual risks and benefits before starting treatment.

Can Ventoxen be used with other medications?

Strong CYP3A inhibitors should be avoided during the ramp-up phase and require a significant dose reduction if used at the maintenance dose. Avoid grapefruit, Seville oranges, and starfruit throughout treatment. Always inform your physician of all medications, supplements, and herbal products you are taking before starting Ventoxen.

Is Ventoxen (Venetoclax) safe during pregnancy or breastfeeding?

No. Ventoxen is not recommended during pregnancy or breastfeeding, as it can cause foetal harm. Women of childbearing potential must use highly effective contraception during treatment and for at least 30 days after the final dose. Please consult your physician before starting treatment if you are pregnant, planning to become pregnant, or breastfeeding.

Can I order Ventoxen (Venetoclax) online with worldwide shipping?

Yes. Mediaid Pharmacy supplies Ventoxen (Venetoclax) 100mg globally with worldwide shipping. Contact us via WhatsApp, phone, or WeChat at +8801773428128 or email us at info@mediaidpharmacy.com to enquire about pricing, availability, and delivery to your country.

Order Ventoxen (Venetoclax) 100mg with Worldwide Shipping

Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com

Message on WhatsApp